| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Michael Rose
Tudor Pop
Rosalio Madrigal
Rosalio Madrigal
| Share Statistics | XERS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,980.0 | $500.9 | 55% |
|
| Shares Out (Mil) | 172.8 | 42.7 | 73% |
|
| Institutional Ownership | 94.7% | 81.3% | 65% |
|
| Float (Mil) | 176.1 | 45.6 | 71% |
|
| Beta | 0.85 | 0.73 | 50% |
|
| Avg Daily Volume (000s) | 2,348 | 303 | 84% |
|
| Price Change (52-week) |
19.6% | 56.3% | 69% |
|
| Growth | XERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 70.3% | 6.1% | 97% |
|
| Net Income (5yr) | 14.9% | (2.4%) | 63% |
|
| EPS (5yr) | 14.9% | 14.9% | 56 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (9.9%) | (15.1%) | 58% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.027 | ($0.090) | $0.197 | |
| Month Ago EPS | $0.033 | ($0.077) | $0.217 | |
| # Rev Up | 0 | 1 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.040 | $0.143 | $0.393 | |
| Year/Year Chg | (115.0%) | (3,100%) | 13,333% | |
| Financials | XERS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $335 | $416 | 37% |
|
| Net Income (TTM) (Mil) | ($17) | ($11) | 25% |
|
| EPS (TTM) | ($0.102) | ($0.700) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | $57 | ($7) | 47% |
|
| Net Cash Flow (TTM) (Mil) | $62 | $6 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $219 | $6 | 51% |
|
| Enterprise Value (Q1) (Mil) | $1,663 | $493 | 47% |
|
| Valuation | XERS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.09 | na |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | XERS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.6% | 69.4% | 92% |
|
| Net Margin | (5.1%) | 3.2% | 25% |
|
| ROA | (4.6%) | (22.2%) | 30% |
|
| ROE | 118.2% | (21.0%) | 97% |
|
| Liabilities to Assets | 102.4% | 32.3% | 95% |
|
| F-Score | 6 | 3 | 67% |
|
Xeris Biopharma Holdings, Inc. did not pass any screens on 10/22/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
